US Oncology Providers and Psychedelic Therapy: 2026 Survey Insights

Oncology Providers' Attitudes Toward Psychedelic-Assisted Therapy

A 2026 study published on PubMed (PMID: 42661611) provides the first large-scale survey of oncology providers' perspectives on psychedelic-assisted therapy for cancer patients. The research, conducted across multiple US cancer centers, found that while a majority of providers expressed cautious optimism about the therapeutic potential of psychedelics—such as psilocybin and MDMA—for addressing existential distress, anxiety, and depression in oncology settings, significant reservations remain regarding safety, regulatory status, and evidence quality.

Respondents included medical oncologists, palliative care specialists, and oncology nurses. Approximately 62% reported interest in referring patients to psychedelic-assisted therapy if it were approved and reimbursed, but only 28% felt personally comfortable recommending such interventions under current regulatory conditions. This gap highlights the importance of both regulatory clarity and provider education.

Mechanisms and Clinical Context: Why Oncology Providers Care

Oncology providers recognize that psychedelic-assisted therapy may address gaps in current psychosocial oncology care. Traditional pharmacological and psychotherapeutic options often fall short in alleviating cancer-related existential distress and end-of-life anxiety. Psychedelics, when administered with psychological support, have shown promise in early-phase trials for improving quality of life and reducing psychological suffering in advanced cancer patients.

Providers in the survey cited the rapid and durable effects observed in recent phase II studies (e.g., NYU Langone, Johns Hopkins) as a reason for their interest. However, many also noted that these studies were small, highly controlled, and may not generalize to broader oncology populations. A non-obvious insight from the survey is that providers with more years in practice were less likely to endorse psychedelic therapy, suggesting that generational shifts in clinical culture may influence future adoption rates more than previously recognized.

Policy and Research Implications: Barriers and Opportunities

The findings have direct implications for clinical trial design, provider education, and policy development. Providers identified several barriers to adoption:

• Regulatory uncertainty: The Schedule I status of most psychedelics under federal law creates legal and institutional hesitancy, even as some states (e.g., Oregon, Colorado) advance medical use frameworks.
• Evidence gaps: Providers called for larger, phase III trials with diverse oncology populations and robust safety monitoring before widespread adoption.
• Training needs: Only 15% of respondents felt adequately informed about psychedelic therapy, underscoring the need for targeted continuing medical education and interdisciplinary guidelines.
• Reimbursement and access: Concerns about insurance coverage and equitable access were frequently cited as practical barriers to implementation.

Policy makers and research sponsors may use these insights to prioritize funding for pragmatic trials, develop standardized training programs, and engage with payers early to address reimbursement pathways. Notably, the survey suggests that provider buy-in may hinge as much on institutional policy and peer norms as on individual attitudes or scientific evidence.

Risks, Unknowns, and the Path Forward

Oncology providers remain wary of several risks associated with psychedelic-assisted therapy. These include potential for psychological destabilization in vulnerable patients, drug interactions with cancer therapeutics, and the risk of off-label or unsupervised use. The survey also highlighted the lack of long-term safety data and the need for clear protocols to manage challenging psychedelic experiences in medically complex populations.

Uncertainties around federal-state policy conflicts and the evolving legal landscape further complicate clinical adoption. Providers expressed concern that premature implementation—without adequate safeguards or evidence—could undermine patient trust and expose institutions to liability.

Looking Ahead: Next Steps for Research, Policy, and Practice

The 2026 PubMed study underscores that oncology providers are open to psychedelic-assisted therapy but require robust evidence, clear guidelines, and institutional support before integrating it into routine cancer care. Future research should focus on pragmatic, multi-site trials that address real-world patient diversity and comorbidities. Policy makers and professional societies can accelerate responsible adoption by clarifying regulatory pathways, supporting provider education, and engaging with payers to ensure equitable access.

This survey also signals that successful integration of psychedelics into oncology will depend on aligning scientific evidence, clinical culture, and health system incentives—a complex interplay that requires ongoing collaboration between researchers, clinicians, regulators, and patient advocates.

Authored by Dr. Jamie L. Carter, MD, MPH. Reviewed by Dr. Jamie L. Carter on 2026-08-29. Research based on first-party PubMed data (PMID: 42661611), with policy and clinical context synthesized from primary regulatory and trial sources.